Langerhans Cell Histiocytosis-Associated Pulmonary Adenocarcinoma: A Word of Caution during Molecular Determinations
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Vassallo, R.; Ryu, J.H.; Schroeder, D.R.; Decker, P.A.; Limper, A.H. Clinical outcomes of pulmonary Langerhans’-cell histiocytosis in adults. N. Engl. J. Med. 2002, 346, 484–490. [Google Scholar] [CrossRef] [PubMed]
- Kaya, A.; Savaş, Y.; Sen, E.; Sak, S.D.; Güngör, A.; Gönüllü, U. Histiocytosis X and bronchopulmonary adenocarcinoma: A rare coexistence. Can. Respir. J. 2002, 9, 431–432. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Howarth, D.M.; Gilchrist, G.S.; Mullan, B.P.; Wiseman, G.A.; Edmonson, J.H.; Schomberg, P.J. Langerhans cell histiocytosis: Diagnosis, natural history, management, and outcome. Cancer 1999, 85, 2278–2290. [Google Scholar] [CrossRef]
- Lombard, C.M.; Medeiros, L.J.; Colby, T.V. Pulmonary histiocytosis X and carcinoma. Arch. Pathol. Lab Med. 1987, 111, 339–341. [Google Scholar] [PubMed]
- Sadoun, D.; Vaylet, F.; Valeyre, D.; Natali, F.; Georges, R.; Allard, P.; Battesti, J.P. Bronchogenic carcinoma in patients with pulmonary histiocytosis X. Chest 1992, 101, 1610–1613. [Google Scholar] [CrossRef] [Green Version]
- Khaliq, M.F.; Noorani, M.M.; Tariq, S.M.; Koirala, A.; Mohamed, H. Pulmonary Langerhans Cell Histiocytosis Associated with Bronchogenic Carcinoma. Cureus 2020, 12, e6634. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ohtsuki, Y.; Uomoto, M.; Hashisuka, Y.; Kato, M.; Iguchi, M.; Lee, G.H.; Furihata, M. A rare case of coexistence of pulmonary adenocarcinoma with Langerhans’ cell histiocytosis. Med. Mol. Morphol. 2008, 41, 175–178. [Google Scholar] [CrossRef]
- Uskul, B.T.; Turker, H.; Bayraktar, O.U.; Onemli, M. Bronchogenic carcinoma developing during a long-term course of pulmonary Langerhans’ cell histiocytosis. Intern. Med. 2009, 48, 359–362. [Google Scholar] [CrossRef]
- Kalchiem-Dekel, O.; Paulk, A.; Kligerman, S.J.; Burke, A.P.; Shah, N.G.; Dixon, R.K. Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung. J. Thorac. Dis. 2017, 9, E1079–E1083. [Google Scholar] [CrossRef] [Green Version]
- Alden, S.L.; Swanson, S.J.; Nishino, M.; Sholl, L.M.; Awad, M.M. BRAF-Mutant pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma. JTO Clin. Res. Rep. 2020, 2, 100127. [Google Scholar] [CrossRef]
- Bhardwaj, H.; Bhardwaj, B.; Levin, D. Pulmonary adenocarcinoma in a young patient of pulmonary langerhans cell histiocytosis (PLCH). J. Thorac. Oncol. 2013, 8, e69–e70. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- von der Thüsen, J.H.; van de Wetering, M.D.; Westermann, A.M.; Heideman, D.A.M.; Thunnissen, E. Bronchioloalveolar adenocarcinoma and pulmonary langerhans cell histiocytosis in a patient with MUTYH-associated polyposis. J. Clin. Oncol. 2011, 29, e188–e190. [Google Scholar] [CrossRef] [PubMed]
- Gencer, A.; Ozcibik, G.; Karakas, F.G.; Sarbay, I.; Batur, S.; Borekci, S.; Turna, A. Two smoking-related lesions in the same pulmonary lobe of squamous cell carcinoma and pulmonary Langerhans cell histiocytosis: A case report. World J. Clin. Cases 2022, 10, 6722–6727. [Google Scholar] [CrossRef] [PubMed]
- Sauter, J.L.; Dacic, S.; Galateau-Salle, F.; Attanoos, R.L.; Butnor, K.J.; Churg, A.; Husain, A.N.; Kadota, K.; Khoor, A.; Nicholson, A.G.; et al. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. J. Thorac. Oncol. 2022, 17, 608–622. [Google Scholar] [CrossRef] [PubMed]
- Shaw, B.; Borchers, M.; Zander, D.; Gupta, N. Pulmonary Langerhans Cell Histiocytosis. Semin. Respir. Crit. Care Med. 2020, 41, 269–279. [Google Scholar] [CrossRef]
- Liu, H.; Osterburg, A.R.; Flury, J.; Swank, Z.; McGraw, D.W.; Gupta, N.; Wikenheiser-Brokamp, K.A.; Kumar, A.; Tazi, A.; Inoue, Y.; et al. MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. JCI Insight 2020, 5, e132048. [Google Scholar] [CrossRef] [Green Version]
- Kobayashi, M.; Tojo, A. The BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis. Blood 2014, 124, 2610–2611. [Google Scholar] [CrossRef] [Green Version]
- Zhang, L.; Pacheco-Rodriguez, G.; Seatgall, W.K.; Kato, J.; Colby, T.V.; Haughey, M.; Moss, J. BRAF and NRAS mutations in circulating Langerhans-like CD1a + cells in a patient with pulmonary Langerhans’ cell histiocytosis. Eur. Respir. J. 2017, 50, 1700521. [Google Scholar] [CrossRef] [Green Version]
- Héritier, S.; Hélias-Rodzewicz, Z.; Lapillonne, H.; Terrones, N.; Garrigou, S.; Normand, C. Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis. Br. J. Haematol. 2017, 178, 457–467. [Google Scholar] [CrossRef] [Green Version]
- Jouenne, F.; Chevret, S.; Bugnet, E.; Clappier, E.; Lorillon, G.; Meignin, V.; Sadoux, A.; Cohen, S.; Haziot, A.; How-Kit, A.; et al. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement. Eur. Respir. J. 2020, 55, 1901190. [Google Scholar] [CrossRef]
- Mourah, S.; How-Kit, A.; Meignin, V.; Gossot, D.; Lorillon, G.; Bugnet, E.; Mauger, F.; Lebbe, C.; Chevret, S.; Tost, J.; et al. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis. Eur. Respir. J. 2016, 47, 1785–1796. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ou, S.I.; Nagasaka, M.; Zhu, V.W. Liquid Biopsy to Identify Actionable Genomic Alterations. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 978–997. [Google Scholar] [CrossRef] [PubMed]
- Yousem, S.A.; Dacic, S.; Nikiforov, Y.E.; Nikiforova, M. Pulmonary Langerhans cell histiocytosis: Profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest 2013, 143, 1679–1684. [Google Scholar] [CrossRef] [PubMed]
- Kamionek, M.; Ahmadi Moghaddam, P.; Sakhdari, A.; Kovach, A.E.; Welch, M.; Meng, X.; Dresser, K.; Tomaszewicz, K.; Cosar, E.F.; Mark, E.J.; et al. Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease. Histopathology 2016, 69, 499–509. [Google Scholar] [CrossRef]
- Roden, A.C.; Hu, X.; Kip, S.; Parrilla Castellar, E.R.; Rumilla, K.M.; Vrana, J.A.; Vassallo, R.; Ryu, J.H.; Yi, E.S. BRAF V600E expression in Langerhans cell histiocytosis: Clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am. J. Surg. Pathol. 2014, 38, 548–551. [Google Scholar] [CrossRef]
- Paik, P.K.; Arcila, M.E.; Fara, M.; Sima, C.S.; Miller, V.A.; Kris, M.G.; Ladanyi, M.; Riely, G.J. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J. Clin. Oncol. 2011, 29, 2046–2051. [Google Scholar] [CrossRef] [Green Version]
- Anglesio, M.S.; Papadopoulos, N.; Ayhan, A.; Nazeran, T.M.; Noë, M.; Horlings, H.M.; Lum, A.; Jones, S.; Senz, J.; Seckin, T.; et al. Cancer-Associated Mutations in Endometriosis without Cancer. N. Engl. J. Med. 2017, 376, 1835–1848. [Google Scholar] [CrossRef] [Green Version]
- Vallvé-Juanico, J.; López-Gil, C.; Ballesteros, A.; Santamaria, X. Endometrial Stromal Cells Circulate in the Bloodstream of Women with Endometriosis: A Pilot Study. Int. J. Mol. Sci. 2019, 20, 3740. [Google Scholar] [CrossRef] [Green Version]
- Hu, Y.; Ulrich, B.C.; Supplee, J.; Kuang, Y.; Lizotte, P.H.; Feeney, N.B.; Guibert, N.M.; Awad, M.M.; Wong, K.K.; Jänne, P.A.; et al. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin. Cancer Res. 2018, 24, 4437–4443. [Google Scholar] [CrossRef] [Green Version]
- Croitoru, V.M.; Cazacu, I.M.; Popescu, I.; Paul, D.; Dima, S.O.; Croitoru, A.E.; Tanase, A.D. Clonal Hematopoiesis and Liquid Biopsy in Gastrointestinal Cancers. Front. Med. 2022, 8, 772166. [Google Scholar] [CrossRef]
- Chan, H.T.; Chin, Y.M.; Nakamura, Y.; Low, S.K. Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. Cancers 2020, 12, 2277. [Google Scholar] [CrossRef] [PubMed]
Reference | Gender | Age | Smoke | Tumor Stage | Genetic Alterations in Lung Cancer | Genetic Alterations in PLCH | Therapy | Outcome |
---|---|---|---|---|---|---|---|---|
Alden et al. | Female | 45 | Current | IIIB | KRAS (p.G12D) | BRAF (p.V600E) | Neoadjuvant chemotherapy; surgery | Alive (>6 months) |
Kalchiem-Dekel et al. | Female | 56 | Current | IV | BRAF (p. V600E) | None | Chemotherapy + radiotherapy | Lost to follow-up |
Our case | Male | 35 | Current | IIB | KRAS (p. G12C) | BRAF (p.V600E) | Surgery; adjuvant chemotherapy | Died of disease (11 months) |
Our case | Male | 75 | Current | IB | KRAS (p.G13C) | None | Surgery; chemotherapy | Died of disease (35 months) |
Our case | Male | 72 | Current | IV | None | None | Chemotherapy | Died of disease (8 months) |
Khaliq et al. | Female | 76 | Current | IIA | N.A. | N.A. | Surgery | N.A. |
Von der Thusen et al. | Male | 14 | Never | IV | KRAS (p. G12C) | N.A. | Chemotherapy | N.A. (colonic carcinoma with MUTYH-associated polyposis) |
Bhardwaj et al. | Female | 28 | Current | IV | None (tested for EGFR and ALK only) | N.A. | Chemotherapy (cisplatin + pemetrexed) | N.A. |
Kaya et al. | Female | 28 | Current | IIA | N.A. | N.A. | Surgery | N.A. |
Ohtsuki et al. | Female | 78 | Never | IB | N.A. | N.A. | Surgery | N.A. |
Gancer et al. | Male | 70 | Current | IA | N.A. (squamous cell carcinoma) | BRAF (p.V600E) | Surgery | Alive (6 months) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Melocchi, L.; Mondoni, M.; Malapelle, U.; Rossi, G. Langerhans Cell Histiocytosis-Associated Pulmonary Adenocarcinoma: A Word of Caution during Molecular Determinations. J. Mol. Pathol. 2022, 3, 286-292. https://doi.org/10.3390/jmp3040024
Melocchi L, Mondoni M, Malapelle U, Rossi G. Langerhans Cell Histiocytosis-Associated Pulmonary Adenocarcinoma: A Word of Caution during Molecular Determinations. Journal of Molecular Pathology. 2022; 3(4):286-292. https://doi.org/10.3390/jmp3040024
Chicago/Turabian StyleMelocchi, Laura, Michele Mondoni, Umberto Malapelle, and Giulio Rossi. 2022. "Langerhans Cell Histiocytosis-Associated Pulmonary Adenocarcinoma: A Word of Caution during Molecular Determinations" Journal of Molecular Pathology 3, no. 4: 286-292. https://doi.org/10.3390/jmp3040024